Search research articles
Contact Us
Filters
Showing results (281-290 of 303) with videos related to
Page
of 31
Sort By:
Nature Communications
|
May 6, 2026
Discovery of a paralog-selective p300 protein degrader with potent anti-cancer activity in hematological malignancies
Marwa S Asem, Yan Zhai, Xiaohong Song, et al.
Blood
|
January 31, 2023
Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia
Stephen K Tahir, Emiliano Calvo, Benedito A Carneiro, et al.
The Journal of Biological Chemistry
|
October 28, 2004
A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase
Shane Atwell, Jason M Adams, John Badger, et al.
European Journal of Dental Education : Official Journal of the Association for Dental Education in Europe
|
June 8, 2018
Oral Medicine for undergraduate dental students in the United Kingdom and Ireland-A curriculum
A J Mighell, C Freeman, P A Atkin, et al.
The EMBO Journal
|
December 20, 2003
Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator
Hal A Lewis, Sean G Buchanan, Stephen K Burley, et al.
European Journal of Dental Education : Official Journal of the Association for Dental Education in Europe
|
July 19, 2011
Clinical medical sciences for undergraduate dental students in the United Kingdom and Ireland - a curriculum
A J Mighell, P A Atkin, K Webster, et al.
Molecular Cancer Therapeutics
|
February 28, 2018
Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate
Andrew C Phillips, Erwin R Boghaert, Kedar S Vaidya, et al.
Journal of Medicinal Chemistry
|
March 27, 2010
Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor
Thomas D Penning, Gui-Dong Zhu, Jianchun Gong, et al.
Investigational New Drugs
|
January 1, 2013
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
S Betty Yan, Victoria L Peek, Rose Ajamie, et al.
Journal of Medicinal Chemistry
|
October 1, 2024
Discovery of Potent Azetidine-Benzoxazole MerTK Inhibitors with <i>In Vivo</i> Target Engagement
Robin R Frey, Navendu Jana, Jacob V Gorman, et al.
Page
of 31
Search research articles
Search
Showing results (281-290 of 303) with videos related to
Sort By:
Page
of 31
Nature Communications
|
May 6, 2026
Discovery of a paralog-selective p300 protein degrader with potent anti-cancer activity in hematological malignancies
Marwa S Asem, Yan Zhai, Xiaohong Song, et al.
Blood
|
January 31, 2023
Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia
Stephen K Tahir, Emiliano Calvo, Benedito A Carneiro, et al.
The Journal of Biological Chemistry
|
October 28, 2004
A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase
Shane Atwell, Jason M Adams, John Badger, et al.
European Journal of Dental Education : Official Journal of the Association for Dental Education in Europe
|
June 8, 2018
Oral Medicine for undergraduate dental students in the United Kingdom and Ireland-A curriculum
A J Mighell, C Freeman, P A Atkin, et al.
The EMBO Journal
|
December 20, 2003
Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator
Hal A Lewis, Sean G Buchanan, Stephen K Burley, et al.
European Journal of Dental Education : Official Journal of the Association for Dental Education in Europe
|
July 19, 2011
Clinical medical sciences for undergraduate dental students in the United Kingdom and Ireland - a curriculum
A J Mighell, P A Atkin, K Webster, et al.
Molecular Cancer Therapeutics
|
February 28, 2018
Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate
Andrew C Phillips, Erwin R Boghaert, Kedar S Vaidya, et al.
Journal of Medicinal Chemistry
|
March 27, 2010
Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor
Thomas D Penning, Gui-Dong Zhu, Jianchun Gong, et al.
Investigational New Drugs
|
January 1, 2013
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
S Betty Yan, Victoria L Peek, Rose Ajamie, et al.
Journal of Medicinal Chemistry
|
October 1, 2024
Discovery of Potent Azetidine-Benzoxazole MerTK Inhibitors with <i>In Vivo</i> Target Engagement
Robin R Frey, Navendu Jana, Jacob V Gorman, et al.
Page
of 31